Actively Recruiting
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
Led by Arsenal Biosciences, Inc. · Updated on 2026-05-14
190
Participants Needed
8
Research Sites
276 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).
CONDITIONS
Official Title
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least 18 years of age at the time of signing informed consent
- Histologically confirmed adenocarcinoma of the prostate with documented progressive metastatic castration-resistant prostate cancer (mCRPC) based on PCWG3 criteria
- Prior treatment with at least one novel androgen receptor pathway inhibitor (ARPI) therapy
- PSMA positive by PSMA PET scan
- Measurable disease by RECIST 1.1 criteria or evaluable disease via measurable PSA (greater than or equal to 1 ng/mL) per PCWG3 criteria
- Adequate organ function
You will not qualify if you...
- Any prior systemic therapy for castration-resistant prostate cancer within 14 days before scheduled leukapheresis
- Presence of central nervous system metastatic disease, leptomeningeal disease, or spinal cord compression
- Unwillingness to participate in an extended safety monitoring period
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 8 locations
1
City of Hope
Duarte, California, United States, 91010
Actively Recruiting
2
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Actively Recruiting
3
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
4
University of Iowa and Holden Comprehensive Cancer Center
Iowa City, Iowa, United States, 52242
Actively Recruiting
5
The University of Kansas Cancer Center
Fairway, Kansas, United States, 66205
Actively Recruiting
6
University of Minnesota
Minneapolis, Minnesota, United States, 55455
Actively Recruiting
7
Perlmutter Cancer Center - NYU Langone Health
New York, New York, United States, 10016
Actively Recruiting
8
Fred Hutchinson Cancer Center
Seattle, Washington, United States, 98109
Actively Recruiting
Research Team
A
Arsenal Biosciences, Inc.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here